Biologic License Application submission expected for 2025

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients | Hansa Biopharma

(www.hansabiopharma.com)

"ConfIdeS trial is expected to conclude in mid-2024."

"To accelerate randomization, Hansa has increased overall site activation up to 25 sites, continued enrollment beyond the targeted 64 patients, ..."

Tjek også: Clinical pipeline update & Commercial update.

"Total cash and equivalents stood at SEK 908 million (USD 83m) end of September 2023 which is expected to finance Hansa’s operations into 2025, as previously guided."